MK-677 with ipamorelin
MK-677 (ibutamoren) with ipamorelin, run as one protocol
Written by Aaron CuhaReviewed Sep 2026
Also known as: Ibutamoren with ipamorelin, Oral plus injectable GH stack
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
This one is not a vial. It is a pill every day plus a shot. People run them together because one is slow and easy and one is fast. Both press the same switch. So this is one thing done twice, not two things.
What people take it for
- Building or holding muscle.
- Better sleep.
- Eating more, when that is the goal.
- Feeling less worn down with age.
What the trials actually showed
The pair has never been tested. But the pill half has the best trial in this whole corner of the site. Sixty five healthy adults aged 60 to 81 took 25 mg a day or a dummy pill for two years. Growth hormone and IGF-1 went back up to young adult levels. Fat free mass went up 1.1 kg in the drug group and down 0.5 kg in the dummy group. Body cell mass went up 0.8 kg against a 1.0 kg drop. That is real, and it is also about a kilogram over two years. The trial did not show a benefit for strength or for how well people functioned. The shot half has one trial, in 117 people after bowel surgery, and it did not beat a dummy shot. One more thing about that kilogram. Fat free mass counts body water, and this drug class makes you hold water. So part of it is not muscle.
What people report
Reports, not trial results
The good
- Deep sleep, especially in the first month.
- A big jump in appetite, if that is what you want.
The bad
- A very large appetite increase. For many people this is the whole experience.
- Water retention, puffy hands and feet, and a fast scale jump people mistake for muscle.
- Numb or tingling fingers.
- Higher fasting blood sugar. This is the most common lab change people report and it is the number to watch.
- People say the shot adds little on top of the pill, which is exactly what you would expect when both press the same switch.
Where these come from: Peptide and gym forums plus clinic write-ups. The appetite and water effects also show up in the controlled work on this drug class.
My bottom line
The pill has a two year trial and it bought about a kilogram of fat free mass with no strength gain. Adding the shot presses the same button again. Watch your blood sugar.
An opinion, not a finding. I am a coach, not a doctor.
Overview
Not one vial but one protocol: a daily oral secretagogue alongside an injected one. Both act at the same receptor, so this is a single mechanism delivered twice. MK-677 is the only component in the growth hormone section of this database with a two-year randomised trial, and that trial showed fat-free mass rose 1.1 kg against a 0.5 kg fall on placebo, with no significant strength or function benefit.
People run these together because one is convenient and slow and the other is injected and fast, and the combination feels like covering both. Pharmacologically it is one receptor, hit twice.
MK-677 is an orally active ghrelin-receptor agonist. Ipamorelin is an injected ghrelin-receptor agonist. Neither is a GHRH agent, so nothing in this protocol supplies the second mechanism that the two-receptor rationale in this category depends on. A person running both has doubled up on the same target and left the other one empty.
What makes this pairing worth a page is that MK-677 carries the best trial in the class. Sixty five healthy adults aged 60 to 81 took 25 mg orally once a day or placebo for two years in a double-blind randomised modified-crossover design. Growth hormone and IGF-1 rose into the young adult range without serious adverse effects. Fat-free mass increased by 1.1 kg on MK-677 and fell by 0.5 kg on placebo. Body cell mass, measured as intracellular water, went up 0.8 kg against a 1.0 kg fall. Those are real numbers from a real trial, and they are also modest, and the trial did not show a significant benefit on strength or function.
Against that, ipamorelin has one randomised controlled trial, in 117 bowel resection patients, given intravenously, where it was safe and did not beat placebo on time to tolerating a solid meal.
The half-life mismatch is the practical problem. MK-677 is taken once a day and holds the axis elevated around the clock; ipamorelin clears in hours and produces a pulse. Growth hormone is normally secreted in pulses against a low background, and a continuous elevation is a different physiological state from a pulse. Adding a pulse on top of a raised baseline is not the same as either, and nobody has measured what it does.
Mechanism of action
Both components are agonists at the growth hormone secretagogue receptor. MK-677 is orally bioavailable with a long enough duration to sustain raised growth hormone and IGF-1 across the day; ipamorelin is injected and short acting. The shared receptor means the two are additive rather than complementary, and the sustained versus pulsatile difference is a pharmacodynamic question that has not been studied when the two are combined.
Human evidence
Each component has been studied alone and the pairing has not. The best trial in the pair is a positive but modest two-year result on body composition with no strength or function benefit.
- The pairing: no published study, no registered trial.
- MK-677: two years, 65 healthy older adults, 25 mg daily. Fat-free mass up 1.1 kg against 0.5 kg down on placebo; growth hormone and IGF-1 restored to young adult range; no significant benefit shown on strength or function.
- Ipamorelin: one randomised trial, 117 post-surgical patients, intravenous, safe, endpoint not met.
- Two ghrelin-receptor agonists together: never studied in people.
What this does not tell you: The MK-677 trial measured composition, not performance, and the gain was about a kilogram of fat-free mass over two years. Fat-free mass includes water, and sustained ghrelin-receptor agonism is known to cause fluid retention, so part of that number is not muscle.
What it has been measured to do
Measured in people
Goals MK-677 with ipamorelin has been measured for in a human being, most people first. Counts come from the study lines on this page and deliberately undercount.
- Gut and digestion117 people · 1 study
- Keeping or building muscle65 people · 1 study
- Growth hormone and IGF-165 people · 1 study
What people using it report
Uncontrolled and self-selected, so it cannot show that anything works. It is still the best guide on this page to what people actually do with MK-677 with ipamorelin, what they expect, and what goes wrong. The full account, including the negative reports, is below.
31 of the 36 indexed goals have no study of any kind behind MK-677 with ipamorelin
No trial, no animal work, no cell work on this page reports a result for these. That is an absence of evidence rather than evidence of absence, but it does mean anything you have been told about MK-677 with ipamorelin and one of these did not come from a study cited here.
Reading the research record
MK-677's trial is the honest centre of this page and it cuts both ways. It is the only two-year randomised evidence in this class, it is positive on its primary composition endpoint, and the size of the effect is about one kilogram of fat-free mass against a placebo group that lost half a kilogram. It did not translate into strength or function. Anyone deciding what to expect from a secretagogue protocol should anchor on that number rather than on forum accounts.
The two known trade-offs with sustained ghrelin-receptor agonism are appetite and glucose. MK-677 increases appetite, which is the reason it was also investigated in wasting states, and sustained elevation of the growth hormone axis works against insulin sensitivity. Adding a second agent at the same receptor increases the exposure that drives both.
The evidence, charted
Fig. 1a · evidence scale
182people, across 2 human studies cited here
- 2014 · International Journal of Colorectal Disease11764%
- 2008 · Annals of Internal Medicine6536%
One study holds 64% of these participants, so the total is less independent than its size suggests. Counts are the enrollment each human citation on this page states, which includes observational cohorts where nobody was given the compound. Studies still recruiting are excluded, and only studies cited on this page are counted.
Fig. 1b · evidence mix
2 of 3 citations here are human work, the rest is not.
- Human · given to people267%
- Review · summarises other work133%
Counted from the citation list on this page, typed as this page types it. It understates any literature larger than the sources we cite, and a review counts once however many studies it covers.
Fig. 2 · evidence over time
Evidence spans 3 distinct years, 2008 to 2018, counted from the citation list on this page. The newest citation on file is from 2018, more than five years ago; the published record may have gone quiet.
Fig. 3 · legal status at a glance
US
Not approved
UK
Not approved
AU
Not approved
CA
Not approved
Not approved in any of the four jurisdictions shown. A jurisdiction's classification is a regulatory fact, not a verdict on the science; see Legal status below for the full text and any notes.
Fig. 4 · dose response
No human dose response curve exists
We draw this figure where the data supports it. For this compound in humans it does not, so the panel stays empty rather than borrowing an animal curve and implying it transfers.
Fig. 5 · molecular identity
- Modality
- Blend
- Molecular weight
- Not on file
- Half-life
- Stated in words, not a number
- Sequence length
- None on file
see the exact wording below
Half-life as stated on file: Not defined for the pairing. One component persists far longer than the other, which is why no single schedule fits both, and the pairing has never been measured.
No amino acid sequence is on file for MK-677 with ipamorelin, which is expected: a blend is not built from residues.
Fig. 6 · what is in the vial
No mass split can be drawn for this blend
Sellers do not publish a consistent vial size for MK-677 with ipamorelin, so the share of each component is not knowable from the outside. Splitting the bar evenly would invent the number this page exists to question.
- MK-677 (ibutamoren)amount not stated
- Ipamorelinamount not stated
Component list from the product labels we hold. Amounts are label mass, never a dose.
Key studies & citations
- Human2008
Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial
65 healthy adults aged 60 to 81 took MK-677 25 mg orally once daily or placebo for two years in a double-blind randomised modified-crossover trial. Growth hormone and IGF-1 rose into the healthy young adult range without serious adverse events. Fat-free mass increased 1.1 kg on MK-677 against a 0.5 kg fall on placebo, and body cell mass measured as intracellular water rose 0.8 kg against a 1.0 kg fall. This is the longest randomised trial of any secretagogue in this database.
Annals of Internal Medicine - Human2014
Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients
117 adults after open or laparoscopic bowel resection randomised to intravenous ipamorelin 0.03 mg/kg twice daily or placebo, with time to tolerating a standardised solid meal as the key endpoint. Safety was the main finding. It remains the only randomised controlled trial of ipamorelin in people.
International Journal of Colorectal Disease - Review2018
The Safety and Efficacy of Growth Hormone Secretagogues
A review of oral and injectable secretagogues covering their endocrine effects, the insulin sensitivity and fluid retention signals seen with sustained ghrelin-receptor agonism, and the distance between surrogate hormone endpoints and clinical outcomes.
Sexual Medicine Reviews
What users report
Self-reported experiences, not evidence. Nothing below was measured under controlled conditions, and reports like these cannot separate a real effect from placebo, from the training or diet change that accompanied it, or from what the product actually contained. They are here because knowing what people describe, including what goes wrong, is worth reading alongside the studies.
- Very large appetite increase on the oral component, often the dominant effect people describe.
- Deep sleep, especially in the first month.
- Noticeable water retention, puffy hands and feet, and a fast scale gain that people misread as muscle.
- Numb or tingling fingers, the classic sign of fluid-related nerve compression.
- Higher fasting glucose on bloodwork, which is the most commonly reported laboratory change.
- Little added effect from the injected component on top of the oral one, which is what shared-receptor pharmacology would predict.
Sources: Peptide and bodybuilding forums including r/peptides, plus clinic write-ups. Uncontrolled self-reports. The appetite and fluid retention effects also appear in the controlled literature on sustained ghrelin-receptor agonism.
Frequently asked questions
Do these two do different things?
No. Both are agonists at the growth hormone secretagogue receptor. Running both is one mechanism delivered twice, not two mechanisms.
What did the MK-677 trial actually show?
Over two years in 65 healthy adults aged 60 to 81, fat-free mass rose 1.1 kg against a 0.5 kg fall on placebo, and growth hormone and IGF-1 returned to the young adult range. There was no significant benefit shown on strength or function.
Is the scale weight muscle?
Partly at best. Fat-free mass includes body water, and sustained ghrelin-receptor agonism causes fluid retention. A fast gain in the first weeks is mostly water.
Will this affect my blood sugar?
A sustained rise in the growth hormone axis works against insulin sensitivity, and higher fasting glucose is the most commonly reported laboratory change on the oral component. If you run this, that is the number to watch.
Has the combination been tested?
No. There is no study of MK-677 with ipamorelin, and no study of any two ghrelin-receptor agonists given together in people.